Drug Approval | April 23, 2026
Cipla’s generic Ventolin HFA secures USFDA approval
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Pharma giant targets new standards of care
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Subscribe To Our Newsletter & Stay Updated
